Journal Watch · Journal of Medicinal Chemistry · 2026

Double-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus.

X-ray crystallography revealed that the enhanced potency of <b>3/4i</b> and <b>3/4m</b> primarily arises from strong hydrophobic interactions between the N-terminal staple and the trimeric HR1 coiled coil of RSV F. <i>In vivo</i> pharmacokinetic, imaging, and feasibility studies in RSV-infected Balb/c mice further support intranasal administration as a promising route for delivering these stapled peptides to the lung, highlighting their potential as therapeutics against RSV.

Pidoux N, Roh L, Nicolet N et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.5c02932PMID: 42203199Study type: preclinical (animal / model) study

TL;DR

X-ray crystallography revealed that the enhanced potency of <b>3/4i</b> and <b>3/4m</b> primarily arises from strong hydrophobic interactions between the N-terminal staple and the trimeric HR1 coiled coil of RSV F. <i>In vivo</i> pharmacokinetic, imaging, and feasibility studies in RSV-infected Balb/c mice further support intranasal administration as a promising route for delivering these stapled peptides to the lung, highlighting their potential as therapeutics against RSV.

Key findings

  • Our structural activity relationship (SAR) analysis demonstrates that combining a limited set of staples is sufficient to achieve high antiviral potency.
  • X-ray crystallography revealed that the enhanced potency of <b>3/4i</b> and <b>3/4m</b> primarily arises from strong hydrophobic interactions between the N-terminal staple and the trimeric HR1 coiled coil of RSV F. <i>In vivo</i> pharmacokinetic, imaging, and feasibility studies in RSV-infected Balb/c mice further support intranasal administration as a promising route for delivering these stapled peptides to the lung, highlighting their potential as therapeutics against RSV.

Numbers at a glance (from the abstract)

HR1

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

In this work, we have screened and identified 3 double-stapled peptides derived from a minimal domain of the RSV F heptad repeat, namely <b>3/4i</b>, <b>3/4m</b>, and <b>4/4g</b>, which are potent inhibitors of RSV fusion and remain active against viral escape mutants resistant to small-molecule fusion inhibitors.

Full abstract (original)

Background: Respiratory syncytial virus infection (RSV) is a major global health concern, particularly in infants and elderly populations.

What they did: In this work, we have screened and identified 3 double-stapled peptides derived from a minimal domain of the RSV F heptad repeat, namely <b>3/4i</b>, <b>3/4m</b>, and <b>4/4g</b>, which are potent inhibitors of RSV fusion and remain active against viral escape mutants resistant to small-molecule fusion inhibitors.

Results & conclusions: Our structural activity relationship (SAR) analysis demonstrates that combining a limited set of staples is sufficient to achieve high antiviral potency. X-ray crystallography revealed that the enhanced potency of <b>3/4i</b> and <b>3/4m</b> primarily arises from strong hydrophobic interactions between the N-terminal staple and the trimeric HR1 coiled coil of RSV F. <i>In vivo</i> pharmacokinetic, imaging, and feasibility studies in RSV-infected Balb/c mice further support intranasal administration as a promising route for delivering these stapled peptides to the lung, highlighting their potential as therapeutics against RSV.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02932 · PubMed 42203199.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

X-ray crystallography revealed that the enhanced potency of <b>3/4i</b> and <b>3/4m</b> primarily arises from strong hydrophobic interactions between the N-terminal staple and the trimeric HR1 coiled coil of RSV F. <i>In vivo</i> pharmacokinetic, imaging, and feasibility studies in RSV-infected Balb/c mice further support intranasal administration as a promising route for delivering these stapled peptides to the lung, highlighting their potential as therapeutics against RSV.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. In this work, we have screened and identified 3 double-stapled peptides derived from a minimal domain of the RSV F heptad repeat, namely <b>3/4i</b>, <b>3/4m</b>, and <b>4/4g</b>, which are potent inhibitors of RSV fusion and remain active against viral escape mutants resistant to small-molecule fusion inhibitors.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02932. PubMed ID: 42203199. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Pidoux N, Roh L, Nicolet N et al.. Double-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c02932.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/double-stapled-peptide-scan-yields-potent-fusion-inhibitors-of-respirato-c02932/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides